The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews (Correa de Costa, et al, 2025)
"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."
Spotlight: Ketamine Harm Reduction
Prevention & Treatment in Ketamine Use Disorder - When a medicine becomes a poison
Spotlight: The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal (Lehane, et al, 2025)
"These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. "
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)
"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."